EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Philogen SpA's Enterprise Value is €633.9 Mil.
Philogen SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €264.3 Mil. Therefore, Philogen SpA's EV-to-FCF for today is 2.40.
The historical rank and industry rank for Philogen SpA's EV-to-FCF or its related term are showing as below:
CHIX:PHILm'
s EV-to-FCF Range Over the Past 10 Years
Min: -76.18 Med: -27.25 Max: 25.75
Current: 2.15
During the past 6 years, the highest EV-to-FCF of Philogen SpA was 25.75. The lowest was -76.18. And the median was -27.25.
CHIX:PHILm's EV-to-FCF is ranked better than 72.59% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs CHIX:PHILm: 2.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Philogen SpA's PE Ratio (TTM) for today is calculated as:
Philogen SpA's share price for today is €15.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Philogen SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €5.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Philogen SpA EV-to-FCF Related Terms
Philogen SpA EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Philogen SpA's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PHILM vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Philogen SpA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Philogen SpA's EV-to-FCF falls into.
Philogen SpA's current Enterprise Value is €633.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Philogen SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €264.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Philogen SpA (CHIX:PHILM) has a EV-to-FCF of 2.40 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Philogen SpA and its competitors. According to the industry distribution chart, Philogen SpA ranks #91 out of 332 companies in the Biotechnology industry, placing it in the top 27.4%.
Is Philogen SpA's EV-to-FCF too high?
Philogen SpA's current EV-to-FCF is 2.40. The Biotechnology industry median EV-to-FCF is 16.26. Philogen SpA's value of 2.40 is 85.2% below this industry median. Based on the distribution chart, Philogen SpA ranks #91 out of 332 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Philogen SpA has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #91 out of 332 companies for EV-to-FCF. This puts Philogen SpA in the upper half of its industry. The industry median EV-to-FCF is 16.26. Philogen SpA's value of 2.40 is 85.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Philogen SpA's current EV-to-FCF of 2.40 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Philogen SpA and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Philogen SpA's current EV-to-FCF is 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Philogen SpA (CHIX:PHILM) has a current EV-to-FCF of 2.40. The stock's GF Value™ is €148.55, compared to a current price of €15.20 — trading 89.8% below its estimated fair value. The current EV-to-FCF is 2.40 and 85.2% below the Biotechnology industry median of 16.26. Philogen SpA's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Philogen SpA (CHIX:PHILM), the current EV-to-FCF is 2.40 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (CHIX:PHILM) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €15.20 is trading 89.8% below its estimated GF Value™ of €148.55.
Key valuation signals for CHIX:PHILM:
EV-to-FCF: 2.40
GF Value™: €148.55 vs. price of €15.20 (89.8% below fair value)
Industry Position: 85.2% below the Biotechnology median (#91 of 332)
No single metric tells the full story. See the CHIX:PHILM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
62GF Score
Get the complete analysis for CHIX:PHILM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PHILM has been successfully added to your 
